Article - Limited access to UNIGE
Other version: http://onlinelibrary.wiley.com/store/10.1111/j.1610-0387.2009.07312_supp.x/asset/j.1610-0387.2009.07312_supp.x.pdf?v=...
Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab"
|Published in||Journal der Deutschen Dermatologischen Gesellschaft. 2010, vol. 8, no. 1, p. 65-66|
|Abstract||In February 2009, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) had recommended the suspension of efalizumab's (Raptiva) marketing authorization, because its benefits in the treatment of psoriasis were modest, while there was a risk of serious side effects in patients receiving the medicine, including the occurrence of progressive multifocal leukoencephalopathy (PML). The guideline group has changed the guideline accordingly.|
|Keywords||Antibodies, Monoclonal/adverse effects/*therapeutic use — Dermatology/*standards — European Union — *Evidence-Based Medicine — Humans — *Practice Guidelines as Topic — Psoriasis/*drug therapy|
|NAST, Alexander et al. Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab". In: Journal der Deutschen Dermatologischen Gesellschaft, 2010, vol. 8, n° 1, p. 65-66. https://archive-ouverte.unige.ch/unige:29866|